CORVUS PHARMACEUTICALS INC

CRVS stock represents ownership in Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company. Its underlying business focuses on developing immunotherapies for cancer and other diseases. Investors buy and sell CRVS shares on a public exchange, and the stock's price reflects the market's collective view of the company's prospects and risks.

CRVS operates in the biotechnology and pharmaceutical industry. Specifically, it is a clinical-stage biopharmaceutical company engaged in developing immune-based therapies, including monoclonal antibodies and small molecule drugs, aimed at treating cancer and other serious conditions.

Recent performance data for CRVS changes daily with market trading. To see the latest price movement, percentage change, and recent trend, refer to the real-time or historical price information displayed on this page.

Since CRVS is a clinical-stage biopharmaceutical company, it often has little or no product revenue and may report net losses, making traditional valuation metrics less useful. Investors frequently examine cash burn, pipeline progress, and risk-adjusted potential instead. Current valuation-related figures should be taken from the latest data shown on this page.

CRVS shares trade during standard U.S. market hours, typically 9:30 a.m. to 4:00 p.m. Eastern Time, unless an exchange holiday applies. Some brokers offer pre-market and after-hours trading sessions, but liquidity may be lower and price swings can be wider outside the regular session.

Key risks for CRVS include clinical trial failures, regulatory delays, competition, and the need for additional financing to fund research. Because it is a clinical-stage biopharmaceutical company, CRVS may lack steady product revenue and could be volatile around data releases, financing news, or pipeline updates.